EarningsQ3 2026 Earnings Report
MX:WST Q3 2026 EPS Results
Actual EPS$49.97
Consensus EPS$41.35
Beat/MissBeat by +$8.62
One Year Ago EPS$36.82
MX:WST Q3 2026 Revenue Results
Actual Revenue$16.43B
Expected Revenue$15.54B
Beat/MissBeat by +$888.28M
YoY Revenue Growth+8.72%
Earnings Announcement Details
QuarterQ3 2026
Date10/29/2026
TimeBefore Open
Conference CallThursday, October 29, 2026
MX:WST Upcoming Earnings
West Pharmaceutical Services's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:WST Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was strongly positive: West exceeded Q3 revenue and earnings expectations, delivered broad-based organic growth, expanded margins significantly, raised full-year revenue and EPS guidance, and reported strong demand across HVP Components, GLP-1, biologics, and multiple geographies. The main challenges were the West Vantage decline, SmartDose 3.5 divestiture-related revenue effects, a 5% year-to-date free-cash-flow decrease, and expected moderation in HVP Delivery Device growth in Q4.Company Guidance
Strong Third-Quarter Revenue and Earnings
Q3 revenue was $874 million, up 8.7% on a reported basis and 11.9% organically, exceeding expectations. Adjusted EPS was $2.66, up 36% year over year and $0.47 above the midpoint of prior guidance.
Proprietary Products Delivered Broad-Based Growth
The Proprietary Products segment grew 16.6% organically. HVP Components revenue was $467 million, up 20% organically and representing 53% of total company revenue, driven by robust biologics growth, continued GLP-1 strength, and positive HVP product mix.
HVP Components Growth Outside GLP-1 and Upgrade Opportunity
HVP Components growth outside GLP-1s was in the high teens organically. The company added over 200 upgrade projects this year, with Annex 1 regulations driving upgrades in Europe and increasing upgrade activity in other geographies as regulatory frameworks raise containment-system requirements.
GLP-1 Business Continued to Accelerate
GLP-1 HVP revenue grew well into the [30s] organically and represented just under 12% of total quarterly revenue. Management said there were no one-time items in the quarter and described GLP-1 as a durable, longer-term growth driver supported by existing-product adoption, new therapeutic categories, next-generation molecules, generics, and expanded access.
HVP Delivery Devices Posted 26% Organic Growth
HVP Delivery Device revenue was $99 million, flat on a reported basis and up 26% organically after excluding currency and the SmartDose 3.5 divestiture. Crystal Zenith and Administration Systems both contributed to growth.
Standard Products Grew Organically
Standard Products revenue was $163 million, up 3% on an organic basis.
Geographic Growth Was Strong Across All Regions
Asia Pacific revenue grew 42%, led by India and China and supported in part by the introduction of GLP-1s in both markets. The Americas grew 12%, while EMEA grew 6%. Asia Pacific represented 11% of total company revenue.
Significant Gross and Operating Margin Expansion
Total company gross margin was 39.7%, up 310 basis points year over year. Adjusted operating margin was 25.3%, up 420 basis points, driven primarily by gross-margin expansion, positive HVP mix, price contribution, plant performance, and SG&A leverage.
Inflationary Pressures Were Offset
Management stated that inflationary pressures on the cost base were offset through good plant performance and some cost recovery via pass-through.
Positive Pricing Contribution
Price contributed just over 4 percentage points of growth in Q3. Management said the long-term planning assumption remains 2%-3% price growth, while pricing was ahead of that level this year.
Capacity Expansion and Operational Improvements
West has been adding and training new shifts, optimizing its global network, and increasing capacity. At the Eschweiler site in Germany, increased automation is helping expand output and support network optimization and customer service levels.
New HVP Finishing Capacity Investments
The company is beginning a new wave of meaningful capital investments to expand HVP finishing capacity in Europe and the U.S. The projects are being added within the existing footprint and are expected to take approximately 18 to 24 months to come online.
Capital Spending Remains Within the Target Range
Nine-month capital expenditures were $125 million, lower than initially planned. Full-year CapEx is now expected to be $215 million-$220 million, within the company’s 6%-8% of revenue corridor, albeit at the low end.
Balance Sheet and Shareholder Returns
West upsized its revolver to $750 million and renewed it for another five years. Year to date, the company paid $47 million in dividends, announced its 34th consecutive year of dividend increases with an 18% increase in the quarterly dividend, and repurchased just over 2.4 million shares for $685 million.
Raised Full-Year Revenue Guidance
Full-year revenue guidance increased to $3.41 billion-$3.42 billion from $3.345 billion-$3.38 billion. Full-year organic sales growth guidance increased to 11.3%-11.6% from 10%-11%. The outlook includes a 120-basis-point full-year FX benefit and a 160-basis-point reported-growth impact from the SmartDose 3.5 divestiture.
Raised Full-Year EPS and Margin Guidance
Full-year adjusted EPS guidance increased to $9.38-$9.48 from $8.85-$9.05, representing expected year-over-year growth of 29%-30%. Full-year operating margins are expected to expand by almost 300 basis points.
Constructive Fourth-Quarter Outlook
Q4 revenue guidance is $820 million-$830 million and represents 6%-7% organic revenue growth. Management expects Q4 growth to be driven by double-digit growth in HVP Components.
Strategic Customer and Continuous-Improvement Priorities
Management said West is on the very short list of preferred partners because of its reputation, technical expertise, regulatory expertise, quality, and delivery performance. Priorities include developing more strategic customer relationships, improving demand planning and innovation adoption, and strengthening continuous-improvement efforts through digitization and automation.
West Vantage Strategy Is Progressing
Management said West Vantage is progressing as expected, with higher-value-added contracts ramping, a good funnel of opportunities, and continued execution by the team. The company is shifting toward higher-value drug-handling components while rolling off legacy programs.
Long-Term Biologics and HVP Growth Drivers
Biologics revenue grew 26% year to date. Management cited record levels of scientific innovation and a record clinical-development pipeline, with an increasing percentage represented by biologics, as continued growth drivers. HVP is expected to grow faster than the overall company, causing its revenue mix to continue rising over time.
Large-Scale Patient and Customer Impact
West is on track to deliver over 40 billion highly critical components to customers this year.
Disciplined M&A Approach
Management said the initial focus will be on strengthening organic growth. Given West’s financial profile and organic prospects, the bar for M&A is described as incredibly high, with transactions expected to amplify the financial profile and provide value to customers and shareholders.
Existing Footprint Supports Near-Term Demand
Management said the existing capacity is sufficient to continue supporting demand, with significant labor investments already increasing capacity at several HVP sites. Tech transfers are also being used to level-load facilities and improve utilization of the existing footprint.
MX:WST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed